MAPK1 and melanoma: Additionally, a preclinical study has shown that anti‐EGF vaccination antibodies enhanced the activity of MAPK/ERK and PI3K/AKT inhibitors and reduced the proliferative effects of NRAS mutation melanoma cell lines [475].